BR112013008008A2 - composto, composição farmacêutica e processo para preparar um composto - Google Patents
composto, composição farmacêutica e processo para preparar um compostoInfo
- Publication number
- BR112013008008A2 BR112013008008A2 BR112013008008A BR112013008008A BR112013008008A2 BR 112013008008 A2 BR112013008008 A2 BR 112013008008A2 BR 112013008008 A BR112013008008 A BR 112013008008A BR 112013008008 A BR112013008008 A BR 112013008008A BR 112013008008 A2 BR112013008008 A2 BR 112013008008A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2279DE2010 | 2010-09-24 | ||
PCT/IB2011/054229 WO2012038944A1 (en) | 2010-09-24 | 2011-09-26 | Matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013008008A2 true BR112013008008A2 (pt) | 2016-06-21 |
Family
ID=44903306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013008008A BR112013008008A2 (pt) | 2010-09-24 | 2011-09-26 | composto, composição farmacêutica e processo para preparar um composto |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2619179A1 (pt) |
JP (1) | JP2013538821A (pt) |
KR (1) | KR20140045287A (pt) |
CN (1) | CN103249719A (pt) |
AU (1) | AU2011306398A1 (pt) |
BR (1) | BR112013008008A2 (pt) |
CA (1) | CA2812362A1 (pt) |
MX (1) | MX2013003362A (pt) |
SG (1) | SG188641A1 (pt) |
WO (1) | WO2012038944A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
JP2019533641A (ja) | 2016-09-08 | 2019-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態およびその使用 |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
MX2023009682A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962529A (en) | 1994-06-22 | 1999-10-05 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5863915A (en) * | 1996-05-15 | 1999-01-26 | Bayer Corporation | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease |
KR20010072089A (ko) | 1998-07-30 | 2001-07-31 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제제로서 트리시클릭술폰아미드 및 그의 유도체 |
US6366675B1 (en) | 1999-05-21 | 2002-04-02 | Kohji Toda | Sound pressure detecting system |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
-
2011
- 2011-09-26 BR BR112013008008A patent/BR112013008008A2/pt not_active Application Discontinuation
- 2011-09-26 JP JP2013529763A patent/JP2013538821A/ja not_active Withdrawn
- 2011-09-26 AU AU2011306398A patent/AU2011306398A1/en not_active Abandoned
- 2011-09-26 CA CA2812362A patent/CA2812362A1/en not_active Abandoned
- 2011-09-26 SG SG2013021654A patent/SG188641A1/en unknown
- 2011-09-26 WO PCT/IB2011/054229 patent/WO2012038944A1/en active Application Filing
- 2011-09-26 EP EP11776885.3A patent/EP2619179A1/en not_active Withdrawn
- 2011-09-26 KR KR1020137010369A patent/KR20140045287A/ko not_active Application Discontinuation
- 2011-09-26 MX MX2013003362A patent/MX2013003362A/es unknown
- 2011-09-26 CN CN2011800564244A patent/CN103249719A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN103249719A (zh) | 2013-08-14 |
EP2619179A1 (en) | 2013-07-31 |
CA2812362A1 (en) | 2012-03-29 |
WO2012038944A1 (en) | 2012-03-29 |
AU2011306398A1 (en) | 2013-05-02 |
SG188641A1 (en) | 2013-04-30 |
KR20140045287A (ko) | 2014-04-16 |
JP2013538821A (ja) | 2013-10-17 |
MX2013003362A (es) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
BRPI0909691A2 (pt) | Composto, método para preparar um composto, e, composição farmacêutica | |
BR112014007645A2 (pt) | composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica | |
BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
BR112014003798A2 (pt) | método para fabricar um composto, e, composto | |
BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
BRPI1012018A2 (pt) | processo para preparar um composto | |
BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
BR112014001418A2 (pt) | compostos, processo para a preparação dos compostos, e, uso dos compostos | |
BRPI1011888A2 (pt) | processo para preparar um composto, e, composição. | |
BR112013028959A2 (pt) | composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
BRPI0914674A2 (pt) | processo para preparação de um pó | |
BR112014013354A2 (pt) | processo para a preparação de um polímero, composição, composto, e, formulação | |
BR112013018945A2 (pt) | processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos. | |
BR112013002036A2 (pt) | processo para preparar um plastificante, plastificante e composição polimérica | |
BR112013012873A2 (pt) | processo para preparar uma n, n-dialquiletanolamina | |
BR112013007040A2 (pt) | "método para preparar um composto e composto" | |
BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
BR112014007568A2 (pt) | composição farmacêutica, uso e processo para preparar a mesma | |
BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica | |
BRPI1016109A2 (pt) | "composto, composição farmacêutica, e, processo para preparar um composto" | |
BR112012029225A2 (pt) | processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral | |
BR112013005986A2 (pt) | processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo | |
BR112012002130A2 (pt) | processo para a preparação de composto,e, composto intermediário |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |